John LaMattina is the former Senior Vice President and President of Global R&D at Pfizer, where he oversaw the drug discovery and development efforts of over 12,000 colleagues in the United States, Europe and Asia. He retired from this position in December, 2007 after serving for 30 years. During his Pfizer tenure, Dr. LaMattina oversaw the research efforts that led to new drugs to treat cancer, smoking addiction, rheumatoid arthritis, and neuropathic pain. He is the author of numerous scientific publications and U.S. patents as well as two books: "Drug Truths: Dispelling the Myths About Pharma R&D", and "Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?" Dr. LaMattina serves on the Board of Directors of PureTech Health, Ligand Pharmaceuticals, Zafgen, Vedanta Biosciences, and is Chairman of the Board of Gelesis. Dr. LaMattina received the 1998 Boston College Alumni Award of Excellence in Science, an Honorary Doctor of Science degree from the University of New Hampshire in 2007, and the American Chemical Society’s Earle B. Barnes Award for Leadership in Chemical Research Management in 2010. Dr. LaMattina received a BS in Chemistry from Boston College in 1971, and a PhD in Organic Chemistry from the University of New Hampshire in 1975.